{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:14:14Z","timestamp":1790000054879,"version":"4.0.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by ineffective clonal hematopoiesis, splenomegaly, bone marrow fibrosis, and the propensity for transformation to acute myeloid leukemia. The discovery of mutations in <jats:italic>JAK2<\/jats:italic>, <jats:italic>CALR<\/jats:italic>, and <jats:italic>MPL<\/jats:italic> have uncovered activated JAK-STAT signaling as a primary driver of MF, supporting a rationale for JAK inhibition. However, JAK inhibition alone is insufficient for long-term remission and offers modest, if any, disease-modifying effects. Given this, there is great interest in identifying mechanisms that cooperate with JAK-STAT signaling to predict disease progression and rationally guide the development of novel therapies. This review outlines the latest discoveries in the biology of MF, discusses current clinical management of patients with MF, and summarizes the ongoing clinical trials that hope to change the landscape of MF treatment.<\/jats:p>","DOI":"10.1038\/s41408-019-0236-2","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T12:02:51Z","timestamp":1568203371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Myelofibrosis in 2019: moving beyond JAK2 inhibition"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9994-8579","authenticated-orcid":false,"given":"Michael","family":"Schieber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Crispino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"key":"236_CR1","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/ajh.23703","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi, A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 89, 915\u2013925 (2014).","journal-title":"Am. J. Hematol."},{"key":"236_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405 (2016).","journal-title":"Blood"},{"key":"236_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek, S. et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Journal of Hematol. Oncol. 10, 55 (2017).","journal-title":"Journal of Hematol. Oncol."},{"key":"236_CR4","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison, C. N. et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30, 1701 (2016).","journal-title":"Leukemia"},{"key":"236_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2017","unstructured":"Guglielmelli, P. et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J. Clin. Oncol. 36, 310\u2013318 (2017).","journal-title":"J. Clin. Oncol."},{"key":"236_CR6","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A. et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 32, 1631\u20131642 (2018).","journal-title":"Leukemia"},{"key":"236_CR7","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A. et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J. Clin. Oncol. 36, 1769\u20131770 (2018).","journal-title":"J. Clin. Oncol."},{"key":"236_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","volume":"1","author":"A Tefferi","year":"2015","unstructured":"Tefferi, A. & Pardanani, A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 1, 97\u2013105 (2015).","journal-title":"JAMA Oncol."},{"key":"236_CR9","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","volume":"108","author":"C Lacout","year":"2006","unstructured":"Lacout, C. et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108, 1652\u20131660 (2006).","journal-title":"Blood"},{"key":"236_CR10","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","volume":"111","author":"R Tiedt","year":"2008","unstructured":"Tiedt, R. et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111, 3931\u20133940 (2008).","journal-title":"Blood"},{"key":"236_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman, Y. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLOS Med. 3, e270 (2006).","journal-title":"PLOS Med."},{"key":"236_CR12","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl, T. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 369, 2379\u20132390 (2013).","journal-title":"N. Engl. J. Med."},{"key":"236_CR13","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia, J. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 369, 2391\u20132405 (2013).","journal-title":"N. Engl. J. Med."},{"key":"236_CR14","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1056\/NEJMc1400499","volume":"370","author":"F Passamonti","year":"2014","unstructured":"Passamonti, F., Caramazza, D. & Maffioli, M. JAK inhibitor in CALR-mutant myelofibrosis. N. Engl. J. Med. 370, 1168 (2014).","journal-title":"N. Engl. J. Med."},{"key":"236_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2018-05-850263","volume":"132","author":"C Pecquet","year":"2018","unstructured":"Pecquet, C. et al. Secreted mutant calreticulins as rogue cytokines trigger thrombopoietin receptor activation specifically in CALR mutated cells: perspectives for MPN therapy. Blood 132, 4 (2018).","journal-title":"Blood"},{"key":"236_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc3343","volume":"12","author":"AH Shih","year":"2012","unstructured":"Shih, A. H., Abdel-Wahab, O., Patel, J. P. & Levine, R. L. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12, 599 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"236_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nature09586","volume":"468","author":"M Ko","year":"2010","unstructured":"Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839 (2010).","journal-title":"Nature"},{"key":"236_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11\u201324 (2011).","journal-title":"Cancer Cell"},{"key":"236_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553\u2013567 (2010).","journal-title":"Cancer Cell"},{"key":"236_CR20","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.molcel.2014.12.023","volume":"57","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol. Cell 57, 662\u2013673 (2015).","journal-title":"Mol. Cell"},{"key":"236_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/leu.2011.253","volume":"26","author":"A Tefferi","year":"2012","unstructured":"Tefferi, A. et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 26, 475 (2012).","journal-title":"Leukemia"},{"key":"236_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/blood-2014-04-567024","volume":"125","author":"E Chen","year":"2015","unstructured":"Chen, E. et al. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood 125, 327\u2013335 (2015).","journal-title":"Blood"},{"key":"236_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1182\/blood-2014-04-555508","volume":"125","author":"T Kameda","year":"2015","unstructured":"Kameda, T. et al. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood 125, 304\u2013315 (2015).","journal-title":"Blood"},{"key":"236_CR24","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ng.621","volume":"42","author":"T Ernst","year":"2010","unstructured":"Ernst, T. et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42, 722 (2010).","journal-title":"Nat. Genet."},{"key":"236_CR25","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1182\/blood-2005-09-3585","volume":"107","author":"LM Kamminga","year":"2006","unstructured":"Kamminga, L. M. et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 107, 2170\u20132179 (2006).","journal-title":"Blood"},{"key":"236_CR26","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","volume":"118","author":"P Guglielmelli","year":"2011","unstructured":"Guglielmelli, P. et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 118, 5227\u20135234 (2011).","journal-title":"Blood"},{"key":"236_CR27","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1182\/blood-2015-11-679431","volume":"127","author":"Y Yang","year":"2016","unstructured":"Yang, Y., Akada, H., Nath, D., Hutchison, R. E. & Mohi, G. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm. Blood 127, 3410\u20133423 (2016).","journal-title":"Blood"},{"key":"236_CR28","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20151136","volume":"213","author":"T Shimizu","year":"2016","unstructured":"Shimizu, T. et al. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. The J. Exp. Med. 213, 1479\u20131496 (2016).","journal-title":"The J. Exp. Med."},{"key":"236_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/bjh.13129","volume":"168","author":"K Harada\u2010Shirado","year":"2015","unstructured":"Harada\u2010Shirado, K. et al. Dysregulation of the MIRLET 7\/HMGA 2 axis with methylation of the CDKN 2A promoter in myeloproliferative neoplasms. Br. J. Haematol. 168, 338\u2013349 (2015).","journal-title":"Br. J. Haematol."},{"key":"236_CR30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","volume":"22","author":"O Abdel-Wahab","year":"2012","unstructured":"Abdel-Wahab, O. et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22, 180\u2013193 (2012).","journal-title":"Cancer Cell"},{"key":"236_CR31","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1084\/jem.20131141","volume":"210","author":"O Abdel-Wahab","year":"2013","unstructured":"Abdel-Wahab, O. et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J. Exp. Med. 210, 2641\u20132659 (2013).","journal-title":"J. Exp. Med."},{"key":"236_CR32","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood-2009-09-245381","volume":"115","author":"FX Schaub","year":"2010","unstructured":"Schaub, F. X. et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 115, 2003\u20132007 (2010).","journal-title":"Blood"},{"key":"236_CR33","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1084\/jem.20151121","volume":"213","author":"G Sashida","year":"2016","unstructured":"Sashida, G. et al. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. J. Exp. Med. 213, 1459\u20131477 (2016).","journal-title":"J. Exp. Med."},{"key":"236_CR34","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.1158\/1078-0432.CCR-13-0905","volume":"19","author":"E Evrot","year":"2013","unstructured":"Evrot, E. et al. JAK1\/2 and pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. Clin. Cancer Res. 19, 6230\u20136241 (2013).","journal-title":"Clin. Cancer Res."},{"key":"236_CR35","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A. et al. U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia 32, 2274\u20132278 (2018).","journal-title":"Leukemia"},{"key":"236_CR36","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","volume":"27","author":"E Kim","year":"2015","unstructured":"Kim, E. et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27, 617\u2013630 (2015).","journal-title":"Cancer Cell"},{"key":"236_CR37","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616\u20133627 (2013).","journal-title":"Blood"},{"key":"236_CR38","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nm.4097","volume":"22","author":"SC-W Lee","year":"2016","unstructured":"Lee, S. C.-W. et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat. Med. 22, 672\u2013678 (2016).","journal-title":"Nat. Med."},{"key":"236_CR39","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","volume":"110","author":"A Theocharides","year":"2007","unstructured":"Theocharides, A. et al. Leukemic blasts in transformed JAK2-V617F\u2013positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110, 375\u2013379 (2007).","journal-title":"Blood"},{"key":"236_CR40","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1073\/pnas.1407792111","volume":"111","author":"R Rampal","year":"2014","unstructured":"Rampal, R. et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc. Natl Acad. Sci. USA 111, 5401\u20135410 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"236_CR41","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg, P. et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123, 2220\u20132228 (2014).","journal-title":"Blood"},{"key":"236_CR42","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/leu.2014.289","volume":"29","author":"EK Engle","year":"2014","unstructured":"Engle, E. K. et al. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia 29, 869 (2014).","journal-title":"Leukemia"},{"key":"236_CR43","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld, J. et al. Classification and personalized prognosis in myeloproliferative neoplasms. N. Engl. J. Med. 379, 1416\u20131430 (2018).","journal-title":"N. Engl. J. Med."},{"key":"236_CR44","doi-asserted-by":"crossref","unstructured":"Mesa R., Jamieson C. NCCN Guidelines Version 2.2018 Myeloproliferative Neoplasms (2017).","DOI":"10.6004\/jnccn.2017.0157"},{"key":"236_CR45","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ejh.12846","volume":"98","author":"JC Hern\u00e1ndez\u2010Boluda","year":"2017","unstructured":"Hern\u00e1ndez\u2010Boluda, J. C. et al. Predictive factors for anemia response to erythropoiesis\u2010stimulating agents in myelofibrosis. Eur. J. Haematol. 98, 407\u2013414 (2017).","journal-title":"Eur. J. Haematol."},{"key":"236_CR46","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799\u2013807 (2012).","journal-title":"N. Engl. J. Med."},{"key":"236_CR47","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787\u2013798 (2012).","journal-title":"N. Engl. J. Med."},{"key":"236_CR48","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363, 1117\u20131127 (2010).","journal-title":"N. Engl. J. Med."},{"key":"236_CR49","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1182\/blood-2016-11-731604","volume":"129","author":"F Cervantes","year":"2017","unstructured":"Cervantes, F. & Pereira, A. Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood 129, 832\u2013837 (2017).","journal-title":"Blood"},{"key":"236_CR50","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","volume":"100","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi, A. M. et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 100, 1139\u20131145 (2015).","journal-title":"Haematologica"},{"key":"236_CR51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","volume":"11","author":"HM Kvasnicka","year":"2018","unstructured":"Kvasnicka, H. M. et al. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J. Hematol. Oncol. 11, 42 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"236_CR52","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood-2018-03-785907","volume":"132","author":"O Odenike","year":"2018","unstructured":"Odenike, O. How I treat blast phase of Philadelphia-negative myeloproliferative neoplasms. Blood 132, 2339\u20132350 (2018).","journal-title":"Blood"},{"key":"236_CR53","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.leukres.2015.06.001","volume":"39","author":"T Badar","year":"2015","unstructured":"Badar, T. et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic\/acute myeloid leukemia phase. Leuk. Res. 39, 950\u2013956 (2015).","journal-title":"Leuk. Res."},{"key":"236_CR54","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood-2018-99-111935","volume":"132","author":"RK Rampal","year":"2018","unstructured":"Rampal, R. K. et al. Efficacy of combined ruxolitinib and decitabine in patients with accelerated and blast-phase myeloproliferative neoplasms: results of a phase II study (MPN-RC 109 trial). Blood 132, 3027 (2018).","journal-title":"Blood"},{"key":"236_CR55","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","volume":"102","author":"HJ Deeg","year":"2003","unstructured":"Deeg, H. J. et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102, 3912\u20133918 (2003).","journal-title":"Blood"},{"key":"236_CR56","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","volume":"16","author":"KK Ballen","year":"2010","unstructured":"Ballen, K. K. et al. Outcome of transplantation for myelofibrosis. Biol. Blood Marrow Transplant. 16, 358\u2013367 (2010).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"236_CR57","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","volume":"125","author":"N Kr\u00f6ger","year":"2015","unstructured":"Kr\u00f6ger, N. et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis. Blood 125, 3347\u20133350 (2015).","journal-title":"Blood"},{"key":"236_CR58","doi-asserted-by":"publisher","first-page":"7071","DOI":"10.1200\/JCO.2018.36.15_suppl.7071","volume":"36","author":"J Poulose","year":"2018","unstructured":"Poulose, J. et al. Impact of ruxolitinib in myelofibrosis post allogeneic stem cell transplant: a pilot study. J. Clin. Oncol. 36, 7071 (2018).","journal-title":"J. Clin. Oncol."},{"key":"236_CR59","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.bbmt.2017.10.037","volume":"24","author":"RB Salit","year":"2018","unstructured":"Salit, R. B. & Deeg, H. J. Transplant decisions in patients with myelofibrosis: should mutations be the judge? Biol. Blood Marrow Transplant. 24, 649\u2013658 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"236_CR60","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.bbmt.2015.09.005","volume":"21","author":"HJ Deeg","year":"2015","unstructured":"Deeg, H. J. et al. Hematopoietic cell transplantation as curative therapy for patients with myelofibrosis: long-term success in all age groups. Biol. Blood Marrow Transplant. 21, 1883\u20131887 (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"236_CR61","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1182\/blood-2018-99-113255","volume":"132","author":"G Daghia","year":"2018","unstructured":"Daghia, G. et al. High cure rate by allogeneic stem cell transplantation for myelofibrosis patients aged 65 or older. Blood 132, 4637 (2018).","journal-title":"Blood"},{"key":"236_CR62","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3324\/haematol.2016.148924","volume":"102","author":"V Gupta","year":"2016","unstructured":"Gupta, V. et al. A phase 1\/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica 102, 94\u2013102 (2016).","journal-title":"Haematologica"},{"key":"236_CR63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison, C. N. et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 5, 73\u201381 (2018).","journal-title":"Lancet Haematol."},{"key":"236_CR64","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","volume":"4","author":"RA Mesa","year":"2017","unstructured":"Mesa, R. A. et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 4, e225\u2013e236 (2017).","journal-title":"Lancet Haematol."},{"key":"236_CR65","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas, J. et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 4, 652\u2013659 (2018).","journal-title":"JAMA Oncol."},{"key":"236_CR66","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.2217\/fon.15.200","volume":"11","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek, S. & Komrokji, R. S. A comprehensive review of pacritinib in myelofibrosis. Future Oncol. 11, 2819\u20132830 (2015).","journal-title":"Future Oncol."},{"key":"236_CR67","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1182\/blood-2013-02-484832","volume":"125","author":"RS Komrokji","year":"2015","unstructured":"Komrokji, R. S. et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2\/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood 125, 2649\u20132655 (2015).","journal-title":"Blood"},{"key":"236_CR68","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani, A. et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 1, 643\u2013651 (2015).","journal-title":"JAMA Oncol."},{"key":"236_CR69","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison, C. N. et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 4, 317\u2013324 (2017).","journal-title":"Lancet Haematol."},{"key":"236_CR70","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","volume":"110","author":"SO Ciurea","year":"2007","unstructured":"Ciurea, S. O. et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 110, 986\u2013993 (2007).","journal-title":"Blood"},{"key":"236_CR71","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cell.2012.06.032","volume":"150","author":"Q Wen","year":"2012","unstructured":"Wen, Q. et al. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell 150, 575\u2013589 (2012).","journal-title":"Cell"},{"key":"236_CR72","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2014.14","volume":"34","author":"B Goldenson","year":"2014","unstructured":"Goldenson, B. & Crispino, J. D. The aurora kinases in cell cycle and leukemia. Oncogene 34, 537 (2014).","journal-title":"Oncogene"},{"key":"236_CR73","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/nm.3995","volume":"21","author":"Q Jeremy Wen","year":"2015","unstructured":"Jeremy Wen, Q. et al. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat. Med. 21, 1473 (2015).","journal-title":"Nat. Med."},{"issue":"16","key":"236_CR74","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","volume":"25","author":"Naseema Gangat","year":"2019","unstructured":"Gangat N, et al. Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. Clinical Cancer Research 25, 4898\u2013906 (2019).","journal-title":"Clinical Cancer Research"},{"key":"236_CR75","doi-asserted-by":"crossref","unstructured":"Yue L., et al. Preclinical efficacy of TGF-beta receptor I kinase inhibitor, galunisertib, in myelofibrosis. Am. Soc. Hematol. 136, 603 (2015).","DOI":"10.1182\/blood.V126.23.603.603"},{"key":"236_CR76","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood.V128.22.478.478","volume":"128","author":"P Bose","year":"2016","unstructured":"Bose, P. et al. Phase-2 study of sotatercept (ACE-011) in myeloproliferative neoplasm-associated myelofibrosis and anemia. Blood 128, 478 (2016).","journal-title":"Blood"},{"key":"236_CR77","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7083","volume":"36","author":"RA Mesa","year":"2018","unstructured":"Mesa, R. A. et al. A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence. J. Clin. Oncol. 36, 7083 (2018).","journal-title":"J. Clin. Oncol."},{"key":"236_CR78","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2018-02-834820","volume":"131","author":"R Kramann","year":"2018","unstructured":"Kramann, R. & Schneider, R. K. The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis. Blood 131, 2111\u20132119 (2018).","journal-title":"Blood"},{"key":"236_CR79","doi-asserted-by":"crossref","unstructured":"Verstovsek S., et al. PRM-151 in myelofibrosis: efficacy and safety in an open label extension study. Am. Soc. Hematol. 132, 686 (2018).","DOI":"10.1182\/blood-2018-99-115362"},{"key":"236_CR80","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/modpathol.2015.93","volume":"28","author":"M Pizzi","year":"2015","unstructured":"Pizzi, M., Silver, R. T., Barel, A. & Orazi, A. Recombinant interferon-\u03b1 in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod. Pathol. 28, 1315 (2015).","journal-title":"Mod. Pathol."},{"key":"236_CR81","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2018-99-110785","volume":"132","author":"J-J Kiladjian","year":"2018","unstructured":"Kiladjian, J.-J. et al. Ruxopeg, a multi-center Bayesian phase 1\/2 adaptive randomized trial of the combination of ruxolitinib and pegylated interferon alpha 2a in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis. Blood 132, 581 (2018).","journal-title":"Blood"},{"key":"236_CR82","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/leu.2016.233","volume":"30","author":"M Holmstr\u00f6m","year":"2016","unstructured":"Holmstr\u00f6m, M., Riley, C. H., Svane, I. M., Hasselbalch, H. C. & Andersen, M. H. The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. Leukemia 30, 2413 (2016).","journal-title":"Leukemia"},{"key":"236_CR83","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/leu.2017.214","volume":"32","author":"MO Holmstr\u00f6m","year":"2017","unstructured":"Holmstr\u00f6m, M. O. et al. The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia 32, 429 (2017).","journal-title":"Leukemia"},{"key":"236_CR84","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa1310523","volume":"373","author":"A Tefferi","year":"2015","unstructured":"Tefferi, A. et al. A pilot study of the telomerase inhibitor Imetelstat for myelofibrosis. N. Engl. J. Med. 373, 908\u2013919 (2015).","journal-title":"N. Engl. J. Med."},{"key":"236_CR85","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1182\/bloodadvances.2018022012","volume":"2","author":"X Wang","year":"2018","unstructured":"Wang, X. et al. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv. 2, 2378\u20132388 (2018).","journal-title":"Blood Adv."},{"key":"236_CR86","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood-2018-99-115163","volume":"132","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas, J. et al. Imetelstat is effective treatment for patients with intermediate-2 or high-risk myelofibrosis who have relapsed on or are refractory to Janus kinase inhibitor therapy: results of a phase 2 randomized study of two dose levels. Blood 132, 685 (2018).","journal-title":"Blood"},{"key":"236_CR87","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature13383","volume":"512","author":"L Arranz","year":"2014","unstructured":"Arranz, L. et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature 512, 78 (2014).","journal-title":"Nature"},{"issue":"4","key":"236_CR88","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3324\/haematol.2018.200014","volume":"104","author":"Beatrice Drexler","year":"2018","unstructured":"Drexler B., et al. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase 2 study SAKK 33\/14. Haematologica (2018) 8 November 2018. https:\/\/doi.org\/10.3324\/haematol.2018.200014. [E-pub ahead of print].","journal-title":"Haematologica"},{"key":"236_CR89","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2013-11-536854","volume":"124","author":"M Lu","year":"2014","unstructured":"Lu, M., Xia, L., Li, Y., Wang, X. & Hoffman, R. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon \u03b1 2a target JAK2V617F positive progenitor and stem cells. Blood 124, 771\u2013779 (2014).","journal-title":"Blood"},{"key":"236_CR90","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood-2017-08-784066","volume":"130","author":"AH Wei","year":"2017","unstructured":"Wei, A. H. & Tiong, I. S. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood 130, 2469\u20132474 (2017).","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0236-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0236-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0236-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:14:23Z","timestamp":1671207263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0236-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":90,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["236"],"URL":"https:\/\/doi.org\/10.1038\/s41408-019-0236-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]},"assertion":[{"value":"17 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.S. has consulted for Apexx Oncology and Incyte. J.D.C. receives research funding from Scholar Rock and Forma Therapeutics, is a consultant to Sierra Oncology, and is the scientific advisor of the MPN Research Foundation. M.S. declares no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"74"}}